COMPOSITIONS AND METHODS OF TREATING PULMONARY HYPERTENSION
Provided are formulations comprising therapeutically effective amounts of ambrisentan or a pharmaceutically acceptable salt thereof and tadalafil or a pharmaceutically acceptable salt thereof and methods of treating and/or preventing pulmonary hypertension by administration of the formulations.
1 - 32 . (canceled)
33 . A composition comprising ambrisentan and tadalafil, wherein the weight ratio of the ambrisentan to the tadalafil is about 1:2 or about 1:3.
34 . The composition of claim 1 , wherein the weight ratio of the ambrisentan to the tadalafil is about 1:2.
35 . The composition of claim 1 , wherein the ambrisentan to the tadalafil are co-formulated.
36 . The composition of claim 1 , which is formulated for parenteral administration.
37 . The composition of claim 1 , which is formulated for oral administration.
38 . The composition of claim 37 , which is in a tablet form or capsule form.
39 . The composition of claim 1 , wherein the amount of ambrisentan is from about 1 mg to about 100 mg.
40 . The composition of claim 1 , wherein the amount of ambrisentan is from about 2 mg to about 20 mg.
41 . The composition of claim 1 , wherein the amount of tadalafil is from about 5 mg to about 500 mg.
42 . The composition of claim 1 , wherein the amount of tadalafil is from about 10 mg to about 100 mg.
43 . The composition of claim 1 , further comprising a drug selected from the group consisting of prostanoids, PDE5 inhibitors other than tadalafil, endothelin receptor antagonists other than ambrisentan, calcium channel blockers, diuretics, anticoagulants, oxygen and combinations thereof.
44 . A tablet or capsule comprising ambrisentan and tadalafil, wherein the weight ratio of the ambrisentan to the tadalafil is about 1:2.
45 . The tablet or capsule of claim 44 , comprising about 5 mg ambrisentan and about 10 mg tadalafil.
46 . The tablet or capsule of claim 44 , comprising about 10 mg ambrisentan and about 20 mg tadalafil.
47 . The tablet or capsule of claim 44 , wherein the ambrisentan and the tadalafil are co-crystallized.
48 . The tablet or capsule of claim 44 , further comprising a drug selected from the group consisting of prostanoids, PDE5 inhibitors other than tadalafil, endothelin receptor antagonists other than ambrisentan, calcium channel blockers, diuretics, anticoagulants, oxygen and combinations thereof.